What The Big C Can Teach Us About Melanoma

The premise, and the part worth taking seriously

"The Big C" ran on Showtime from 2010 to 2013. Its central character, Cathy Jamison, is a suburban teacher diagnosed with stage IV melanoma who decides to live differently.

The show is a comedy-drama, not a medical procedural, and it does not linger on clinical detail. But it picked a real diagnosis with a real meaning. That meaning has shifted a lot since the show first aired.

What melanoma is, and why it is treated so seriously

Skin has layers. The outer layer is the epidermis. It holds keratinocytes, the cells that give rise to basal cell carcinoma and squamous cell carcinoma. It also holds melanocytes, the cells that make pigment. Melanoma starts in melanocytes.

The National Cancer Institute puts the risk plainly. Skin cancer is the most common malignancy diagnosed in the United States. Invasive melanoma is about 1% of skin cancers, but it causes the most deaths.

For 2025 the American Cancer Society put new melanoma cases at 104,960 and deaths at 8,430 in the United States, and NCI's PDQ summary passes those numbers along. Older men are at highest risk. But NCI also notes melanoma is the most common cancer in young adults aged 25 to 29. It is the second most common in people aged 15 to 29.

Location patterns differ by sex. NCI reports melanoma occurs more often on the arms and legs in women, and more often on the trunk, head, and neck in men.

When to get checked

One statistic reframes everything about self-examination. NCI states that more than 50% of melanoma cases arise in apparently normal areas of skin, not from an existing mole.

So watching your moles is necessary but not sufficient. New spots count too.

NCI lists early signs of malignant change in a mole:

• Darker or variable discoloration.
• Itching.
• An increase in size, or the development of satellite lesions nearby.
• Ulceration or bleeding, which are later signs.

The standard checklist is ABCDE, and NCI gives it in full:

• A for asymmetry of the lesion.
• B for border irregularity.
• C for color variation.
• D for diameter greater than 6 mm, roughly the width of a pencil eraser.
• E for evolution, meaning any change in the lesion.

Practical thresholds:

• Any mole that changes in size, shape, or color over weeks to months, at any age.
• A spot that itches, bleeds, or fails to heal.
• A new pigmented spot appearing in adulthood that looks different from your other moles.
• Melanoma can appear on mucosal surfaces and in the eye, so also report a dark spot inside the mouth or nose, or a new dark patch on the iris.

What a diagnosis requires

NCI is specific and prescriptive here, and the specificity matters.

A biopsy, preferably by local excision, should be done for any suspicious lesion. NCI adds a blunt warning. Suspicious lesions should never be shaved off or cauterized. Shaving destroys the depth information that staging depends on.

An experienced pathologist should examine the specimen, so microstaging is possible. NCI notes that telling benign pigmented spots from early melanomas can be genuinely hard. Even experienced dermatopathologists sometimes disagree.

What actually determines prognosis

Melanoma staging does not lean on tumor width. It leans on depth and behavior. NCI lists the prognostic factors built into the current AJCC staging manual:

• Thickness, and how deep the melanoma has invaded.
• Ulceration or bleeding at the primary site.
• The number of regional lymph nodes involved, separating nodes found only on testing from nodes that can be felt.
• Non-nodal regional disease, including small satellite deposits and in-transit spread through the skin.
• Systemic metastasis, and specifically the site: nonvisceral, versus lung, versus other internal organs, versus the central nervous system.
• An elevated blood level of lactate dehydrogenase.

NCI also notes that people who are younger, female, and who have melanomas on their arms or legs generally have better prognoses. It makes a point about time too. The risk of relapse falls a lot as years pass, but late relapses do happen. So long-term follow-up matters, both for catching recurrence and for spotting new lesions.

What stage IV means now

Cathy's diagnosis, stage IV, means the melanoma has spread to distant parts of the body.

That label reads differently in 2026 than it did in 2010. The reason is a class of drugs called checkpoint inhibitors. They release brakes on the immune system so it can attack tumor cells. NCI's guidance names ipilimumab as the first checkpoint inhibitor the Food and Drug Administration approved as adjuvant therapy after surgery for melanoma. It also discusses large randomized trials of nivolumab and pembrolizumab.

A second approach targets a specific mutation. NCI describes combination signal transduction inhibitor therapy with dabrafenib plus trametinib, aimed at melanomas driven by changes in the BRAF gene.

That is why melanoma tissue now gets tested for BRAF status. The mutation, not the appearance of the tumor, decides whether one whole family of drugs is even an option.

What the numbers describe

These figures cover populations and describe no individual.

SEER, the federal cancer statistics program, gives 112,000 new melanomas of the skin in the United States for 2026, about 5.3% of all new cancer diagnoses, and 8,510 deaths — both of them American Cancer Society projections. Five-year relative survival across all stages is 94.7% for people diagnosed from 2016 to 2022. Melanoma is diagnosed most often between ages 65 and 74.

Stage separates outcomes sharply. Drawing on that same 2016–2022 group, SEER records five-year relative survival of 100.0% for localized melanoma, 76.0% once it has reached regional lymph nodes, and 34.0% once it has spread to distant sites. About 77% of cases are found while still localized, and about 5% are distant at diagnosis.

Read those figures against the show's premise. Distant melanoma still carries the worst outlook of the three groups. But 34.0% is a very different number from what a stage IV melanoma diagnosis implied when "The Big C" was written.

What fiction gets right here

The show's core framing is accurate. Melanoma is a small share of skin cancers and causes most skin cancer deaths, precisely because it invades and spreads.

What a 2010 script could not know is how much treatment for advanced melanoma would change in the next decade. Any drama about a cancer is a snapshot. It captures what that diagnosis meant on the day it was written. That is worth remembering whenever a storyline is read as a guide to a real one.

Sources

• NCI: Melanoma Treatment (PDQ) — Health Professional Version
• SEER Cancer Stat Facts: Melanoma of the Skin
• American Cancer Society: Cancer Facts & Statistics
• Television Academy: The Big C — Emmy Awards and Nominations